LUNG - NASDAQ
Pulmonx Corporation
$1.60
+1.9%Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotPulmonx Corporation Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Moderate conversion rate. Some gap between earnings and cash flow may warrant investigation into working capital or non-cash items.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Flat FCF growth. Stable but not expanding—monitor for signs of business maturity or temporary headwinds.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Pulmonx Corporation Cash Flow Statement
LUNG • NASDAQ
| Pulmonx Corporation Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||
-54M | -56.4M | -60.8M | -58.9M | -48.7M | -32.2M | -20.7M | -18.5M | |
1.2M | 1.5M | 1.5M | 4M | 3.2M | 483K | 365K | 270K | |
0.0 | 0.0 | 0.0 | 49K | -6K | 0.0 | 746K | 936K | |
0.0 | 23M | 22.1M | 0.0 | 0.0 | 3.2M | 364K | 366K | |
22.3M | 2.1M | 2.1M | 16.8M | 11.9M | 2.7M | 864K | 36K | |
(0.0) | (556K) | (471K) | (0.0) | (0.0) | (259K) | (196K) | (226K) | |
-1.9M | -1.7M | -2.6M | -7.1M | -7.8M | -4.8M | -2.4M | -1.5M | |
-32.4M | -31.5M | -37.6M | -45.1M | -41.4M | -30.6M | -20.8M | -18.4M | |
INVESTING ACTIVITIES | ||||||||
-452K | -1.4M | -807K | -1.3M | -3.7M | -911K | -720K | -316K | |
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (13.5M) | (16K) | |
-5.7M | -27.9M | -46.2M | -47.2M | -52.6M | (0.0) | -21.5M | (0.0) | |
36.6M | 46.8M | 45M | 44.3M | 10M | 13.6M | 7.9M | 500K | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -13.5M | 16K | |
(30.5M) | (17.5M) | -2M | -4.2M | -46.3M | (12.7M) | -14.2M | (200K) | |
FINANCING ACTIVITIES | ||||||||
1M | 0.0 | 0.0 | 2.6M | 4.5M | 201.4M | 0.0 | 0.0 | |
-100K | -95K | 19.9M | -87K | 0.0 | 33M | 6M | 12M | |
(0.0) | (0.0) | (0.0) | -27K | -26K | (0.0) | -12K | (0.0) | |
0.0 | 1.5M | 1.5M | 0.0 | 0.0 | 446K | -52K | 114K | |
903K | 1.4M | 21.4M | 2.5M | 4.5M | 234.8M | 45.6M | 12.1M | |
CASH FLOW SUMMARY | ||||||||
-92K | 76K | 34K | 145K | 106K | 133K | 22K | 154K | |
-1.2M | -12.6M | -18.2M | -46.7M | -83.1M | 217M | 10.6M | -5.9M | |
71.2M | 83.8M | 102M | 148.7M | 231.8M | 14.8M | 4.1M | 10.1M | |
70M | 71.2M | 83.8M | 102M | 148.7M | 231.8M | 14.8M | 4.1M | |
-32.9M | -33M | -38.4M | -46.5M | -45.1M | -31.5M | -21.5M | -18.7M |
SEC Filings
LUNG - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 04, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 22, 2026 | June 04, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 04, 2026 | March 04, 2026 | 2026 | |
S-3/A S-3/A (Amended) N/A | November 24, 2025 | November 24, 2025 | ||
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 27, 2025 | October 21, 2025 | 2025 |
Related Guides
Continue your LUNG research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.